BLRX:NSD-BioLineRx Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.34

Change

+0.20 (+9.35)%

Market Cap

USD 0.12B

Volume

0.51M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

BioLineRx Ltd (BLRX) Stock Analysis:
Based on the BioLineRx Ltd stock forecasts from 0 analysts, the average analyst target price for BioLineRx Ltd is not available over the next 12 months. BioLineRx Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioLineRx Ltd is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, BioLineRx Ltd’s stock price was USD 2.34. BioLineRx Ltd’s stock price has changed by -0.29 % over the past week, -0.41 % over the past month and -4.49 % over the last year.

About

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell m ...Read More

Company Website : https://www.biolinerx.com

Address : Modi?in Technology Park, Hevel Modi'in, Israel, 7177871

Employees : 38

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.50

52 Week High : 6.34

Short Ratio : 0.69

52 Week Low : 2.05

Shorted Shares : 184,538

200 Day Moving Average : 2.91

Shorted Shares Previous Month : 156,390

50 Day Moving Average : 2.74

Short Percentage : 1.00%

Shares Held by Institutions : 15.32%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

 USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

 USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

 USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

 USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

 USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

 USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

 USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

 USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing BLRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.14% 70% C- 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.14% 70% C- 35% F
Trailing 12 Months  
Capital Gain -4.49% 70% C- 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.49% 70% C- 34% F
Trailing 5 Years  
Capital Gain 131.68% 74% C 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 131.68% 74% C 76% C
Average Annual (5 Year Horizon)  
Capital Gain 77.30% 84% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.30% 84% B 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 145.36% 18% F 10% F
Risk Adjusted Return 53.18% 81% B- 70% C-
Market Capitalization 0.12B 32% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.49 80% B- 67% D+
Price / Cash Flow Ratio -5.18 47% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -72.59% 39% F 22% F
Return on Invested Capital -65.76% 35% F 13% F
Return on Assets -22.61% 58% F 17% F
Debt to Equity Ratio 12.44% 49% F 68% D+
Technical Ratios  
Short Ratio 0.69 89% B+ 81% B-
Short Percent 0.45% 93% A 84% B
Beta 1.50 37% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.